Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 6/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.39 |
| ▸ | FLT1 | P17948 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.38 |
| ▸ | FDPS | P14324 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL863233 | 0.86 | HTR1A (0.45) | EGFRL3MBTL1MAPTTDP1MEN1 | |
| SCHEMBL14925311 | 0.81 | MAOB (0.44) | MAOBEGFRMAPTKMT2AFGFR1 | |
| SCHEMBL5298028 | 0.81 | ALDH1A1 (0.45) | EGFRMAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL13933168 | 0.80 | L3MBTL1 (0.59) | L3MBTL1MAPTTDP1MEN1NPC1 | |
| SCHEMBL19708262 | 0.80 | L3MBTL1 (0.59) | L3MBTL1MAPTTDP1MEN1NPC1 | |
| SCHEMBL19025103 | 0.79 | L3MBTL1 (0.37) | MAOBL3MBTL1TDP1MEN1KMT2A | |
| SCHEMBL15595766 | 0.79 | ALDH1A1 (0.48) | MAOBL3MBTL1MAPTTDP1MEN1 | |
| SCHEMBL15384783 | 0.79 | SLC6A4 (0.49) | MAOBEGFRL3MBTL1MAPTMEN1 | |
| SCHEMBL22964315 | 0.79 | L3MBTL1 (0.50) | MAOBEGFRL3MBTL1MAPTMEN1 | |
| SCHEMBL17525544 | 0.79 | MAPT (0.50) | L3MBTL1MAPTTDP1MEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1651163-B1 | ARYL CARBAMATE OLIGOMERS FOR HYDROLYZABLE PRODRUGS AND PRODRUGS COMPRISING SAME | BIOCON LTD (IN) | 2015-03-04 | — | — | EP | disclosed |
| US-8143366-B2 | Aryl carbamate oligomers for hydrolyzable prodrugs and prodrugs comprising same | BIOCON LIMITED (IN) | 2012-03-27 | — | — | US | disclosed |
| US-20100081782-A1 | ARYL CARBAMATE OLIGOMERS FOR HYDROLYZABLE PRODRUGS AND PRODRUGS COMPRISING SAME | EKWURIBE NNOCHIRI N | 2010-04-01 | — | — | US | disclosed |
| US-7625995-B2 | Aryl carbamate oligomers for hydrolyzable prodrugs and prodrugs comprising same | BIOCON LIMITED (IN) | 2009-12-01 | — | — | US | disclosed |
| US-20080146778-A1 | ARYL CARBAMATE OLIGOMERS FOR HYDROLYZABLE PRODRUGS AND PRODRUGS COMPRISING SAME | BIOCON LIMITED (IN) | 2008-06-19 | — | — | US | disclosed |
| EP-1651163-A4 | ARYL CARBAMATE OLIGOMERS FOR HYDROLYZABLE PRODRUGS AND PRODRUGS COMPRISING SAME | BIOCON LTD (IN) | 2008-03-26 | — | — | EP | disclosed |
| US-7335751-B2 | Aryl carbamate oligomers for hydrolyzable prodrugs and prodrugs comprising same | BIOCON LIMITED (IN) | 2008-02-26 | — | — | US | disclosed |
| US-20060167234-A1 | Aryl carbamate oligomers for hydroilyzable prodrugs and prodrugs comprising same | BIOCON LIMITED (IN) | 2006-07-27 | — | — | US | disclosed |
| EP-1651163-A2 | ARYL CARBAMATE OLIGOMERS FOR HYDROLYZABLE PRODRUGS AND PRODRUGS COMPRISING SAME | Nobex Corporation (US) | 2006-05-03 | — | — | EP | disclosed |
| WO-2005016240-A2 | ARYL CARBAMATE OLIGOMERS FOR HYDROLYZABLE PRODRUGS AND PRODRUGS COMPRISING SAME | NOBEX CORPORATION (US) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167234-A1 | Aryl carbamate oligomers for hydroilyzable prodrugs and prodrugs comprising same | ALK, OGFR, AOX1 | MAOB 1113/4885EGFR 1194/4885L3MBTL1 647/4885 |
| US-20080146778-A1 | ARYL CARBAMATE OLIGOMERS FOR HYDROLYZABLE PRODRUGS AND PRODRUGS COMPRISING SAME | ALK, AOX1, OGFR | MAOB 498/4885EGFR 1286/4885L3MBTL1 655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.